Shares of Jubilant Life Sciences today surged nearly 4 per cent after the company received final approvals from the US health regulator for sale of generic anti-hypertensive Valsartan tablets in the American market.
Jubilant Life rose by 3.69 per cent to settle at Rs 144.85 on the BSE. During the day, it surged 9.91 per cent to Rs 153.55.
At the NSE, it climbed 3.47 per cent to end at Rs 144.50.
In terms of volume, 4.46 lakh shares of the company changed hands at the BSE, while over 19 lakh shares were traded at the NSE during the day.
The company has received final approvals from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Mycophenolate Mofetil capsules and tablets, manufactured by the company's US arm Jubilant Cadista Pharmaceuticals Inc, and Rizatriptan tablets made at Jubilant Generics Ltd, Jubilant Life Sciences had said in a filing to the BSE yesterday.
The approvals are for Mycophenolate Mofetil in the strengths of 250 mg capsules and 500 mg tablets and Rizatriptan tablets in strengths of 5 mg and 10 mg, it added.
